All In Biotech

Drug Trial Radar · NCT05834868

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,040 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,040

Actual

Start

May 6, 2022

Primary completion

Dec 10, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T2DM.

Conditions

  • Type 2 Diabetes

Interventions

  • THDB0206 InjectionDrug

    Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.

  • Insulin Lispro InjectionDrug

    Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of TreatmentTime frame: Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.